Physician profile
Richa M Patel
NPI 1689930091
$3,685.65
in general payments reported to CMS, 2019-2025
30 companies · $270 in 2025
The $270 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,493 · 2020: $267 · 2021: $333 · 2022: $485 · 2023: $458 · 2024: $380 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $719.47 | 2019-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Novo Nordisk INC | $536.98 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $377.58 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $335.11 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $164.72 | 2019-2022 | |
| Beta Bionics, INC. | $162.85 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Boston Scientific Corporation | $145.12 | 2024 | Wavewriter Alpha Prime 16 |
| Xeris Pharmaceuticals, INC. | $133.78 | 2022-2024 | Gvoke Hypopen |
| Valeritas, INC. | $126.52 | 2019 | |
| Amgen INC. | $126.36 | 2019-2021 | |
| Insulet Corporation | $123.54 | 2019-2020 | |
| Abbvie INC. | $90.11 | 2019-2023 | |
| Tandem Diabetes Care, INC. | $88.95 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic Minimed, INC. | $80.92 | 2019 | |
| Mannkind Corporation | $59.40 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $49.75 | 2020 | |
| Abbott Laboratories | $46.09 | 2022-2023 | Freestyle Libre |
| Merck Sharp & Dohme LLC | $44.63 | 2019-2022 | |
| Shire North American Group INC | $31.75 | 2019 | |
| Lifescan, INC. | $30.93 | 2019 | |
| Amarin Pharma, INC. | $30.92 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.87 | 2019 | |
| Amneal Pharmaceuticals LLC | $27.36 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.27 | 2019 | |
| Senseonics, Incorporated | $24.00 | 2019 | |
| Evoke Pharma, INC. | $18.50 | 2024 | |
| Corcept Therapeutics | $16.80 | 2019 | |
| Pfizer INC. | $14.39 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richa Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.